CROSSING - A new treatment for Eosinophilic Esophagitis

Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE) is caused by elevated levels of a type of white blood cell called eosinophils in the oesophagus (the tube from the throat to the stomach). Elevated levels of eosinophils and a protein made by the body called Thymic Stromal Lymphopoietin (TSLP) cause inflammation of the oesophagus.

Tezepelumab is a man-made antibody that works by blocking the effects of TSLP. Antibodies are proteins naturally produced by the body to neutralize foreign substances that enter the body. By blocking the effects of TSLP, tezepelumab may help decrease inflammation in the oesophagus and improve difficulties in swallowing.

We are doing this study to learn more about tezepelumab. We would like to know if it could be an effective and safe treatment for EoE. We also aim to better understand the condition and associated health problems.

Category
Inflammatory Bowel Disease
Trial status
Recruiting
Trial phase
Phase 3 Drug Trial
Late stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
Registry listing
ClinicalTrials.gov: NCT04753697